免缝合主动脉瓣置换联合瓣膜手术
单中心30例严重主动脉瓣狭窄合并二尖瓣病变患者接受Perceval免缝合主动脉瓣置换联合二尖瓣手术(伴或不伴三尖瓣手术),平均年龄73.0±6.6岁,平均随访18±4.5个月,1年非心脏死亡2例,永久起搏器植入1例(3.3%),术中主动脉瓣环上错位3例(10%)均安全取出再植入,随访无结构性瓣膜退化或瓣膜移位,作者认为该技术可行且安全。
要点
- 30例严重主动脉瓣狭窄合并二尖瓣病变患者接受Perceval免缝合主动脉瓣置换联合二尖瓣手术,平均随访18±4.5个月。
- 1年非心脏死亡2例,永久起搏器植入1例(3.3%),术中主动脉瓣环上错位3例(10%)均安全取出再植入。
- 随访期间无结构性瓣膜退化或瓣膜移位,作者认为该技术可行且安全。
核心结论
- 作者认为,Perceval免缝合主动脉瓣置换在严重主动脉瓣狭窄患者中技术可行且安全,即使合并多瓣膜病变和房颤手术也有良好结果。
研究设计与样本
- 单中心研究,2013年1月至2016年6月纳入30例合并严重二尖瓣病变(伴或不伴三尖瓣病变)并接受Perceval免缝合主动脉瓣置换的患者。
主要发现
- 平均年龄73.0±6.6岁(范围63至86岁),男性60%(n=18),平均logistic EuroScore为9.8±4.6。
- 合并手术包括二尖瓣修复8例(26.6%)、二尖瓣置换22例(73.3%)、三尖瓣修复18例(60%)、三尖瓣置换2例(6.6%)、房颤冷冻消融21例(70%)。
- 人工瓣膜中位尺寸为25 mm(大号);随访1年非心脏死亡2例,永久起搏器植入1例(3.3%),术中主动脉瓣环上错位3例(10%)均安全取出再植入。
- 平均随访18±4.5个月(最长3年);行冷冻迷宫术的患者出院时窦性心律恢复率为76.1%(n=16);随访期间无结构性瓣膜退化或瓣膜移位。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Sutureless aortic valve replacement (SU-AVR) is an alternative technique to standard aortic valve replacement. We evaluated our experience with the Perceval SU-AVR with concomitant mitral valve surgery, with or without tricuspid valve surgery, and aimed to discuss the technical considerations. METHODS: From January 2013 through June 2016, 30 patients with concomitant severe mitral valve disease, with or without tricuspid valve disease, underwent SU-AVR with the Perceval prosthesis in a single center. RESULTS: The mean age was 73.0 ± 6.6 years, ranging from 63 to 86 years, and 60% (n = 18) were male. Mean logistic EuroScore of the study cohort was 9.8 ± 4.6. Concomitant procedures consisted of mitral valve repair (n = 8, 26.6%), mitral valve replacement (n = 22, 73.3%), tricuspid valve repair (n = 18, 60%), tricuspid valve replacement (n = 2, 6.6%), and cryoablation for atrial fibrillation (n = 21, 70%). Median prosthesis size was 25 mm (large size). At 1 year, there were 2 deaths from noncardiac causes. One patient (3.3%) had third-degree atrioventricular block requiring permanent pacemaker implantation. Three patients (10%) had intraoperative supra-annular malpositioning of the aortic prosthesis, which was safely removed and reimplanted in all cases. Mean follow-up was 18 ± 4.5 for months (maximum 3 years). During the postoperative period, sinus rhythm restoration rate in patients who underwent the cryo-maze procedure was 76.1% (n = 16) at discharge. There was no structural valve deterioration or migration of the prosthesis at follow-up. CONCLUSIONS: Perceval SU-AVR is a technically feasible and safe procedure in patients with severe aortic stenosis with good results even in the presence of multivalvular disease and atrial fibrillation surgery.
引用
- Baran C, Durdu MS, Gumus F, et al. Sutureless aortic valve replacement with concomitant valvular surgery. J Thorac Cardiovasc Surg. 2018. PMID: 29551538. doi:10.1016/j.jtcvs.2017.12.154
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。